Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 6/20 | 0.60 |
| ▸ | KDR | P35968 | 5/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | IGF1R | P08069 | 4/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.46 |
| ▸ | PAK4 | O96013 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488628 | 0.93 | LCK (0.58) | LCKKDRMAPK14EPHB4EGFR | |
| SCHEMBL6478952 | 0.89 | KDR (0.74) | LCKKDRMAPK14EPHB4EGFR | |
| SCHEMBL6479597 | 0.76 | KDR (0.57) | LCKKDRMAPK14EPHB4EGFR | |
| SCHEMBL6479352 | 0.74 | KDR (0.54) | LCKKDRMAPK14EPHB4EGFR | |
| SCHEMBL6493240 | 0.74 | KDR (0.56) | LCKKDRMAPK14EPHB4EGFR | |
| SCHEMBL6492044 | 0.73 | EPHB4 (0.56) | LCKKDRMAPK14EPHB4EGFR | |
| SCHEMBL14214730 | 0.73 | KDR (0.82) | LCKKDRMAPK14EPHB4EGFR | |
| SCHEMBL14214609 | 0.73 | KDR (0.87) | LCKKDRMAPK14EPHB4IGF1R | |
| SCHEMBL14214612 | 0.72 | KDR (0.82) | LCKKDRMAPK14EPHB4IGF1R | |
| SCHEMBL14214680 | 0.72 | LCK (0.76) | LCKKDRMAPK14IGF1RPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | LCK 1859/4885KDR 4/4885MAPK14 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.